Genetic Signatures Ltd
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, a… Read more
Genetic Signatures Ltd (GSS) - Net Assets
Latest net assets as of June 2025: AU$50.09 Million AUD
Based on the latest financial reports, Genetic Signatures Ltd (GSS) has net assets worth AU$50.09 Million AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$54.63 Million) and total liabilities (AU$4.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$50.09 Million |
| % of Total Assets | 91.69% |
| Annual Growth Rate | N/A |
| 5-Year Change | 1.53% |
| 10-Year Change | 970.43% |
| Growth Volatility | 121.61 |
Genetic Signatures Ltd - Net Assets Trend (2013–2025)
This chart illustrates how Genetic Signatures Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genetic Signatures Ltd (2013–2025)
The table below shows the annual net assets of Genetic Signatures Ltd from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$50.09 Million | -18.02% |
| 2024-06-30 | AU$61.10 Million | +42.38% |
| 2023-06-30 | AU$42.91 Million | -21.69% |
| 2022-06-30 | AU$54.80 Million | +11.07% |
| 2021-06-30 | AU$49.34 Million | +7.43% |
| 2020-06-30 | AU$45.93 Million | +334.56% |
| 2019-06-30 | AU$10.57 Million | -21.12% |
| 2018-06-30 | AU$13.40 Million | -18.72% |
| 2017-06-30 | AU$16.49 Million | +252.27% |
| 2016-06-30 | AU$4.68 Million | -33.69% |
| 2015-06-30 | AU$7.06 Million | -56.38% |
| 2014-06-30 | AU$16.18 Million | +587.83% |
| 2013-06-30 | AU$-3.32 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genetic Signatures Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6476963900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$127.64 Million | 254.82% |
| Other Comprehensive Income | AU$9.56 Million | 19.09% |
| Total Equity | AU$50.09 Million | 100.00% |
Genetic Signatures Ltd Competitors by Market Cap
The table below lists competitors of Genetic Signatures Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Christiani & Nielsen (Thai) Public Company Limited
BK:CNT
|
$8.20 Million |
|
Bangkok Genomics Innovation Pcl
BK:BKGI
|
$8.21 Million |
|
CASH Financial Services Group Limited
F:CFN0
|
$8.21 Million |
|
FORSEE POWER(PROM.)EO-10
F:4OY
|
$8.21 Million |
|
Green World Hotels Co., Ltd.
TWO:8077
|
$8.20 Million |
|
Pion Group AB Series B
ST:PION-B
|
$8.20 Million |
|
Zeo Energy Corp
NASDAQ:ZEO
|
$8.20 Million |
|
Laon People Inc.
KQ:300120
|
$8.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genetic Signatures Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 61,103,000 to 50,093,000, a change of -11,010,000 (-18.0%).
- Net loss of 20,104,000 reduced equity.
- Share repurchases of 554,000 reduced equity.
- New share issuances of 8,769,000 increased equity.
- Other comprehensive income increased equity by 879,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-20.10 Million | -40.13% |
| Share Repurchases | AU$554.00K | -1.11% |
| Share Issuances | AU$8.77 Million | +17.51% |
| Other Comprehensive Income | AU$879.00K | +1.75% |
| Total Change | AU$- | -18.02% |
Book Value vs Market Value Analysis
This analysis compares Genetic Signatures Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.36x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-06-30 | AU$-0.13 | AU$0.08 | x |
| 2014-06-30 | AU$0.23 | AU$0.08 | x |
| 2015-06-30 | AU$0.14 | AU$0.08 | x |
| 2016-06-30 | AU$0.06 | AU$0.08 | x |
| 2017-06-30 | AU$0.17 | AU$0.08 | x |
| 2018-06-30 | AU$0.13 | AU$0.08 | x |
| 2019-06-30 | AU$0.10 | AU$0.08 | x |
| 2020-06-30 | AU$0.35 | AU$0.08 | x |
| 2021-06-30 | AU$0.33 | AU$0.08 | x |
| 2022-06-30 | AU$0.37 | AU$0.08 | x |
| 2023-06-30 | AU$0.29 | AU$0.08 | x |
| 2024-06-30 | AU$0.37 | AU$0.08 | x |
| 2025-06-30 | AU$0.22 | AU$0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genetic Signatures Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -40.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -126.44%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.09x
- Recent ROE (-40.13%) is below the historical average (-21.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -783.88% | 0.28x | 0.00x | AU$-1.68 Million |
| 2014 | -10.68% | -133.73% | 0.08x | 1.02x | AU$-3.35 Million |
| 2015 | -37.68% | -254.88% | 0.13x | 1.11x | AU$-3.36 Million |
| 2016 | -64.67% | -92.68% | 0.55x | 1.27x | AU$-3.49 Million |
| 2017 | -16.20% | -65.75% | 0.23x | 1.07x | AU$-4.32 Million |
| 2018 | -24.28% | -65.16% | 0.34x | 1.09x | AU$-4.59 Million |
| 2019 | -33.04% | -49.72% | 0.58x | 1.15x | AU$-4.55 Million |
| 2020 | -4.54% | -18.52% | 0.23x | 1.08x | AU$-6.68 Million |
| 2021 | 3.56% | 6.21% | 0.52x | 1.10x | AU$-3.18 Million |
| 2022 | 5.59% | 8.65% | 0.59x | 1.09x | AU$-2.42 Million |
| 2023 | -32.74% | -82.96% | 0.35x | 1.14x | AU$-18.34 Million |
| 2024 | -29.23% | -182.90% | 0.15x | 1.10x | AU$-23.97 Million |
| 2025 | -40.13% | -126.44% | 0.29x | 1.09x | AU$-25.11 Million |
Industry Comparison
This section compares Genetic Signatures Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $175,452,925
- Average return on equity (ROE) among peers: -30.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genetic Signatures Ltd (GSS) | AU$50.09 Million | 0.00% | 0.09x | $8.20 Million |
| Australian Clinical Labs Ltd (ACL) | $68.99 Million | 59.80% | 4.31x | $217.50 Million |
| Bcal Diagnostics Ltd (BDX) | $6.22 Million | -116.40% | 0.59x | $10.33 Million |
| Capitol Health Ltd (CAJ) | $144.04 Million | 0.60% | 0.82x | $222.66 Million |
| Cryosite Ltd (CTE) | $1.45 Million | 126.98% | 12.60x | $5.03 Million |
| Healius Ltd (HLS) | $1.04 Billion | -62.05% | 1.87x | $208.81 Million |
| Inoviq Ltd (IIQ) | $2.83 Million | -115.42% | 0.16x | $23.33 Million |
| Microba Life Sciences Ltd (MAP) | $32.49 Million | -45.98% | 0.46x | $10.42 Million |
| Monash Ivf Group Ltd (MVF) | $268.44 Million | 9.37% | 0.33x | $116.82 Million |
| Pacific Edge Ltd (PEB) | $13.91 Million | -128.81% | 0.19x | $89.67 Million |